While a convincing amount of preclinical evidence suggests that the KATP channel subtype Kir6.1/SUR2B is a promising drug target for migraine, translation to patients is pending better pharmacological tools and novel selective inhibitors with a benign side effect profile are needed to prove or disprove this interesting drug target. Here, KCNJ8 is linked to migraine disorder.